Omnicell, Inc. (NASDAQ:OMCL) VP Peter J. Kuipers sold 18,054 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $50.31, for a total transaction of $908,296.74. Following the completion of the sale, the vice president now directly owns 44,236 shares of the company’s stock, valued at approximately $2,225,513.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Omnicell, Inc. (NASDAQ:OMCL) traded down 1.38% during midday trading on Wednesday, reaching $50.15. 309,193 shares of the company were exchanged. The firm has a 50-day moving average price of $44.33 and a 200-day moving average price of $40.56. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $51.25. The company’s market capitalization is $1.87 billion.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.38 EPS. Equities research analysts anticipate that Omnicell, Inc. will post $1.31 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/omnicell-inc-omcl-vp-sells-908296-74-in-stock/1466650.html.

Several brokerages have recently weighed in on OMCL. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. CIBC upped their price target on shares of Omnicell from $43.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 26th. BidaskClub cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. TheStreet cut shares of Omnicell from a “b-” rating to a “c+” rating in a research report on Thursday, May 4th. Finally, Piper Jaffray Companies cut shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price target for the company. in a research report on Friday, April 21st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $49.00.

Several institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Omnicell during the first quarter worth approximately $125,000. LS Investment Advisors LLC boosted its position in shares of Omnicell by 136.3% in the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock worth $145,000 after buying an additional 2,060 shares during the last quarter. State of Alaska Department of Revenue boosted its position in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock worth $165,000 after buying an additional 120 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Omnicell during the first quarter worth approximately $170,000. Finally, Turner Investments LLC acquired a new position in shares of Omnicell during the second quarter worth approximately $181,000. 96.35% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.